Shionogi & Co (JP:4507) has released an update.
Shionogi & Co. reports a decline in revenue and profits for the 1st quarter of FY2024 compared to the previous year, with a notable decrease in prescription drug sales partly offset by growth in overseas subsidiaries and increased royalty income. The company saw a 10.7% drop in revenue and a 28.2% reduction in profits, as it continues to invest heavily in research and development.
For further insights into JP:4507 stock, check out TipRanks’ Stock Analysis page.
